Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"
Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal - 09/04/2023
Date Insider Type Main position Quantity % Market Cap.
09/04/23Free

Executive/Senior Manager

400,000 0.6684%
31/01/23Free

Chief Operating Officer

400,000 0.6686%
31/01/23Free

Chief Executive Officer

700,000 1.1700%
Change 5-day change 1-year change 3-year change Capi.($)
-13.39%-23.18% - - 2.95M
+2.14%+6.81%+72.57%+123.91% 56.65B
-0.49%+6.98%+62.88%+67.95% 47.49B
+0.48%-0.20%-14.93%-15.55% 22.81B
+3.60%+4.81%-0.52%+402.21% 21.37B
+1.30%+0.71%+29.21%-17.51% 16.12B
+3.20%+7.18%+24.07%-34.39% 15.56B
-0.02%-3.13%+27.17%+158.25% 12.91B
0.00%+15.02%+133.24%+273.89% 12.86B
+1.43%-5.06%+23.53% - 11.67B
Average -0.18%+1.74%+39.69%+119.84% 24.16B
Weighted average by Cap. +1.26%+3.17%+45.67%+112.92%
Logo Aravive, Inc.
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).
Employees
23
  1. Stock Market
  2. Stocks
  3. ARAV Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!